UCB is a global biopharmaceutical company. Their mission is to provide novel therapeutic solutions for patients with severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders and oncology.

Business Problem UCB manage a complex portfolio of projects in research and development. To maximize the value of the development portfolio frequent decisions must be made: what priority should be given to different projects? Should a project be out-licensed to another pharmaceutical company? How should resources be allocated in order to maximize the return on investment? In order to make the right decisions it is necessary to have a clear idea of the risks, costs and potential rewards associated with each project, and to understand these factors in a whole-portfolio context.

Tessella Solution Working closely with staff at UCB, Tessella has developed software tools to support all aspects of the development portfolio analysis process. Data input workbooks provide a standard format and guidelines on data entry to help project teams prepare data on a consistent basis across the whole portfolio. They also assist with the quantification of risk and help project teams to visualize how risk is spread across the different phases of development.

This entry was posted in News.